ACI’s 7th annual Maximizing Pharmaceutical Patent Life Cycles conference will take place October 23-24, 2006, at the Helmsley Park Lane hotel in New York City.
This should be an excellent meeting, with the following presentations:
- Striking a Balance: Reconciling the Needs and Interests of Brand Name and Generic Pharmaceutical Companies With Public Policy
- From Product Development to Patent Portfolio Management to Patent Life Cycles: Strategies for a Post-MMA World
- Legislative and Regulatory Update: Of Patents and Politics
- Pharmaceutical Patent Extensions and Hatch-Waxman Reform: Observations and Considerations Relative to Patent Term Adjustment and Patent Term Restoration
- ANDA/Paragraph IV Litigation: New Challenges and New Findings
- Update on FDA Activities Relative to Pharmaceutical Patent Life Cycles (Keynote Address)
- Re-exploring Orange Book Listing and De-listing Strategies
- Exclusivity: Patent and Non-Patent–Traditional Modes
- Present Controversies and Uncertainties in Market Exclusivity
- Brand Name/Generic Pharmaceutical Patent Settlements Revisited
- FTC Initiatives to Promote Competition in the Pharmaceutical Industry (Keynote Address)
- The Safe Harbor: Post-Integra
- Eye on the Supreme Court: Key Patent Cases before the Supreme Court and Their Impact on Pharmaceutical Patent Life Cycles
- Pharmaceutical Patent Developments in the EU, India and China: Implications for Pharmaceutical Patent Life Cycles in the US
Keynote addresses will be given by Elizabeth Dickinson, Assoc. Chief Counsel for Drugs at the FDA, and Suzanne T. Michel, Chief Counsel for Intellectual Property at the FTC. In addition, an optional third day, on October 25th, includes workshops on new strategies for obtaining pharmaceutical patent extensions and updated drafting guidelines for paragraph IV certifications and notice letters.
For more information, visit the conference website. I’ll be attending the meeting; if you’ll be there too, please introduce yourself!
Orange Book Blog 
Leave a comment